List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
14 July 2021 | By Analytik Jena
In this on-demand webinar, based on field experiences with our research partners, Analytik Jena provides an overview of application demands for a reliable sample preparation automation – from a small and easy-to-use workstation, to a fully automated integration solution by Analytik Jena.
Researchers have identified 38 drugs that could be repurposed to treat COVID-19 through a strategy involving virtual screening and cell-based assays.
10 reasons to choose Bethyl antibodies and reagents from Fortis Life Sciences for your applications.
Researchers in Japan propose that the antimalarial drug mefloquine could be repurposed to effectively treat SARS-CoV-2.
Drug analysis at the Francis Crick Institute and University of Dundee has revealed 15 potential antivirals that could lead to new COVID-19 treatments.
Using deep machine learning, researchers have completed the activity profiles, from chemistry to clinical level, for one million molecules.
Learn quick technical tips to optimise your ELISA workflow, including how to: select the right ELISA kit, avoid contamination and normalise data.
Discover the new Octet R series systems, a comprehensive solution for screening and characterising molecular interactions such as protein-protein or protein-drug interactions.
Solutions to help you understand viral diseases and translate your research findings into better treatments and vaccines.
A screening campaign has revealed that small molecule inhibitors of the SOX 11 oncogene are toxic to mantle cell lymphoma in vitro.
A team of scientists has found that a type of cell derived from human stem cells and widely used for brain research and drug development may have been leading researchers astray for years. Here, Dr Raphaël Lis from Weill Cornell Medicine explains how forcing the activity of three known endothelial cell transcription…
To ensure that new drugs are effective and have as little toxicity as possible, they first need to be tested in model systems before entering clinical trials. In this Q&A, Dr Takanori Takebe outlines his research into liver organoids derived from stem cells that can be used to test new…
A major limitation in drug development is the occurrence of drug-candidate toxicity during clinical research. This may occur because tumour-derived cell lines are limited as a pre-clinical model – in part because of an altered metabolic poise. A recent study has revealed a profound plasticity in gene expression and metabolic poise that can…
A small molecule found in a cell-based ultra-high-throughput screening campaign was shown to treat diabetes in cells and mice.
The application of chemical perturbation approaches in phenotypic models is often used to identify protein targets for therapeutic discovery. Increasingly, small molecule fragments which covalently bind to their protein targets are being used to explore the druggable proteome and the resulting fragment‑protein interactions are characterised by chemoproteomic techniques. In this…
